<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158858</url>
  </required_header>
  <id_info>
    <org_study_id>0610-02</org_study_id>
    <nct_id>NCT02158858</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis</brief_title>
  <official_title>A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constellation Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Constellation Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients&#xD;
      with previously treated Acute Leukemia, Myelodysplastic Syndrome,&#xD;
      Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.&#xD;
&#xD;
      Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with&#xD;
      Myelofibrosis.&#xD;
&#xD;
      CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2 (Cohorts 1B and 2B and Arm 3): Evaluate spleen response</measure>
    <time_frame>By imaging after 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Cohorts 1A and 2A): Evaluate the RBC (Red Blood Cell) transfusion independence rate</measure>
    <time_frame>Absence of RBC transfusion and no hemoglobin level below 8 g/dL in the prior 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Arm 4): Evaluate the complete hematological response rate</measure>
    <time_frame>1 cycle (21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2 (Arms 1, 2, and 3): Evaluate the duration of spleen response by imaging</measure>
    <time_frame>Through study completion or end of treatment, up to 24 weeks and beyond</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 (all arms): Evaluate the change in patient reported outcomes</measure>
    <time_frame>Changes from baseline in the total symptom score (MFSAF v4.0) and PGIC after 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 (all arms): area under the curve (AUC)</measure>
    <time_frame>Assessed during Cycle 1 (first 21 days on study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 (all arms): maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Assessed during Cycle 1 (first 21 days on study)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Phase 2 (Arms 1, 2, and 3): Evaluate response category rate</measure>
    <time_frame>Rate of response by the International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria after 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Phase 2 (Arms 1, 2, and 3): Evaluate the rate of RBC transfusion and the RBC transfusion dependence rate</measure>
    <time_frame>Average number of RBC units per subject-month, up to 24 weeks and beyond</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">341</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Preleukemia</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Bone Marrow Disease</condition>
  <condition>Hematological Disease</condition>
  <condition>Precancerous Conditions</condition>
  <condition>Neoplasms</condition>
  <condition>Leukemia</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Essential Thrombocytosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi.(CPI-0610 alone)&#xD;
Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Prior JAKi Combination Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)&#xD;
Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: JAKi Naïve Combination Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open to patients with MF who have not previously received a JAKi. (CPI-0610 + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Essential Thrombocytopenia (ET) Monotherapy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-0610</intervention_name>
    <arm_group_label>Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm</arm_group_label>
    <arm_group_label>Arm 2: Prior JAKi Combination Arm</arm_group_label>
    <arm_group_label>Arm 3: JAKi Naïve Combination Arm</arm_group_label>
    <arm_group_label>Arm 4: Essential Thrombocytopenia (ET) Monotherapy Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <arm_group_label>Arm 2: Prior JAKi Combination Arm</arm_group_label>
    <arm_group_label>Arm 3: JAKi Naïve Combination Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following&#xD;
        criteria:&#xD;
&#xD;
          -  ANC ≥ 1 x 10^9/L without the assistance of granulocyte growth factors&#xD;
&#xD;
          -  Peripheral blood blast count &lt;10%&#xD;
&#xD;
          -  ECOG performance status ≤ 2.&#xD;
&#xD;
          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments&#xD;
&#xD;
          -  No prior treatment with a BET inhibitor&#xD;
&#xD;
          -  Patients must give written informed consent to participate in this study before the&#xD;
             performance of any study-related procedure.&#xD;
&#xD;
        For Arm 1 and 2 the following criteria should be considered:&#xD;
&#xD;
          -  Patients with confirmed diagnosis of MF who meet all of the following criteria&#xD;
&#xD;
          -  Dynamic International Prognostic Scoring System (DIPSS) risk category of&#xD;
             intermediate-2 or higher&#xD;
&#xD;
          -  Spleen volume ≥ 450 cm^3 by MRI or CT for Cohorts 1B and 2B OR RBC transfusion&#xD;
             dependent (defined as an average of ≥2 units of RBC transfusions per month over the 12&#xD;
             weeks prior to enrollment for Cohorts 1A and 2A)&#xD;
&#xD;
          -  At least 2 symptoms measurable (Score ≥ 1) using the Myelofibrosis Symptom Assessment&#xD;
             Form Version 4.0 (MFSAF v4.0)&#xD;
&#xD;
          -  Platelet count ≥ 75 x 10^9/L without the assistance of thrombopoietic factors or&#xD;
             transfusions for at least 14 days&#xD;
&#xD;
        Monotherapy Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant,&#xD;
        resistant, refractory, or lost response to the JAK inhibitor; have not received the JAK&#xD;
        inhibitor within 2 weeks prior to the start of study drug, or are ineligible to be treated&#xD;
        with a JAK inhibitor&#xD;
&#xD;
        Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a stable&#xD;
        dose for a minimum 8 weeks but have disease that is not being adequately controlled by&#xD;
        ruxolitinib&#xD;
&#xD;
        For Arm 3 (JAK inhibitors naïve) the following criteria should be considered:&#xD;
&#xD;
          -  Patients with confirmed diagnosis of MF who meet all of the following criteria&#xD;
&#xD;
          -  Dynamic International Prognostic Scoring System (DIPSS) risk category of&#xD;
             intermediate-2 or higher&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L without the assistance of thrombopoietic factors or&#xD;
             transfusions&#xD;
&#xD;
          -  Spleen volume ≥ 450 cm^3 by MRI/CT&#xD;
&#xD;
          -  At least 2 symptoms measurable (Score ≥ 3) or a total score of ≥ 10 using the MFSAF&#xD;
             v4.0&#xD;
&#xD;
          -  No prior treatment with JAKi allowed&#xD;
&#xD;
        For Arm 4 (ET Expansion) the following criteria should be considered:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of ET&#xD;
&#xD;
          -  High-risk disease, defined as meeting at least one of the following criteria:&#xD;
&#xD;
          -  Age &gt; 60 years&#xD;
&#xD;
          -  Platelet count &gt; 1500 × 10^9/L (at any point during the patient's disease)&#xD;
&#xD;
          -  Previously documented thrombosis, erythromelalgia, or migraine&#xD;
&#xD;
          -  Previous hemorrhage related to ET&#xD;
&#xD;
          -  Diabetes or hypertension requiring pharmacological therapy for &gt; 6 months&#xD;
&#xD;
          -  Have ≥2 symptoms with an average score ≥ 3 over the 7-day period prior to Cycle 1 Day&#xD;
             1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using&#xD;
             the using the MPN SAF&#xD;
&#xD;
               -  Platelets &gt; 600 × 10^9/L&#xD;
&#xD;
               -  Resistant or intolerant to HU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current known active or chronic infection with human immunodeficiency virus (HIV),&#xD;
             Hepatitis B or Hepatitis C.&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac diseases&#xD;
&#xD;
          -  Patients with Child-Pugh Class B or C&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that could significantly&#xD;
             alter the absorption of CPI-0610 and/or ruxolitinib, including any unresolved nausea,&#xD;
             vomiting, or diarrhea that is CTCAE Grade &gt;1&#xD;
&#xD;
          -  Prior treatment with a BET inhibitor.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any other concurrent severe and/or uncontrolled concomitant medical condition that&#xD;
             could compromise participation in the study&#xD;
&#xD;
          -  Patients unwilling or unable to comply with this study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debbie Johnson</last_name>
    <role>Study Director</role>
    <affiliation>Constellation Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Johnson</last_name>
    <phone>617-714-0555</phone>
    <email>debbie.johnson@constellationpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic - Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Reed-Pease</last_name>
      <phone>480-342-6068</phone>
      <email>ReedPease.Christine@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Palmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farzam Hariri</last_name>
      <email>FHariri@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Cancer Clinical Research Office</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Smusz</last_name>
      <phone>904-953-2000</phone>
      <email>Smusz.Iwona@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Candido Rivera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pyone Maung</last_name>
      <phone>312-926-4828</phone>
      <email>pyone.maung@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Brady Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Connolly</last_name>
      <phone>617-726-5131</phone>
      <email>cconnolly1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Gabriela Hobbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D'Andra Featherstone</last_name>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Moshe Talpaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicne Neuromuscular Division Department of neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Gaudin</last_name>
      <phone>314-747-7960</phone>
      <email>nrgaudin@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karyn Gordon</last_name>
      <phone>314-362-0156</phone>
      <email>kdgordon@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmounth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Dougherty</last_name>
      <phone>212-241-8839</phone>
      <email>mikaela.dougherty@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Marina Kremyanskya, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Centre</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Raajit Rampal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Hoberman</last_name>
      <phone>212-746-5269</phone>
      <email>gah4002@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Scandura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romany Gergis</last_name>
      <phone>713-792-9116</phone>
      <email>RGergis@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Prithviraj Bose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Guhl</last_name>
      <phone>414-805-0505</phone>
      <email>jguhl@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Michaelis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Stuyvenberg Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Cox</last_name>
      <phone>(32 3) 217-7448</phone>
      <email>karen.cox@zna.be</email>
    </contact>
    <investigator>
      <last_name>Nikki Granacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Burgge-Oostende - Campus Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Tanghe</last_name>
      <phone>(32 5) 045-3060</phone>
      <email>Valerie.tanghe@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Jan Van Droogenbroeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Tuerlinckx</last_name>
      <phone>(32 1) 634-6880</phone>
      <email>charlotte.tuerlinckx@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Timothy Devos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovais Shaikh</last_name>
      <phone>780-407-3365</phone>
      <email>Ovais.Shaikh@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Elena Liew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tathiana Ruiz</last_name>
      <phone>604-682-2344</phone>
      <email>truiz1@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Lynda Foltz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Valiquette</last_name>
      <phone>905-389-4411</phone>
      <phone_ext>64421</phone_ext>
      <email>valiquette@HHSC.CA</email>
    </contact>
    <investigator>
      <last_name>Brian Leber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylie Martin</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4750</phone_ext>
      <email>Kylie.Martin@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadi Zakaria</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>28326</phone_ext>
      <email>chadi.zakaria.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Shireen Sirhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez - Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Roge</last_name>
      <phone>(33 3) 2044-4290</phone>
      <email>florence.roge@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Cambier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie du Gard - Hematologie clinique</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Alessandra Damiano</last_name>
      <phone>(33 4) 6668-3528</phone>
      <email>MariaAlessandra.DAMIANO@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Jourdan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - Hopital Saint Louis - Centre D'Investigations Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Huang</last_name>
      <phone>(33 01) 4238-5205</phone>
      <email>jin.huang-ext@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Kiladjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Francoise</last_name>
      <phone>(33 5) 3115-6331</phone>
      <email>jeanne.francoise@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Suzanne Tavitian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia Pireyre</last_name>
      <phone>(33 1) 4211-4385</phone>
      <email>laetitia.pireyre@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Ribrag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitta Bienert</last_name>
      <phone>(49 3641) 932-4673</phone>
      <email>Gitta.Bienert@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Heidel Florian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betül Özdemir</last_name>
      <phone>(49 221) 4789-7050</phone>
      <email>betuel.oezdemir@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Christof Scheid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolin Hubert</last_name>
      <phone>(49 341) 971-3050</phone>
      <email>Karolin.Hubert@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Uwe Platzbecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institue of Hematology &quot;L. and A. Seràgnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Dambrosio</last_name>
      <phone>(39 051) 214-4569</phone>
      <email>Federica.dambrosio3@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Palandri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Paoli</last_name>
      <phone>(39 055) 794-7331</phone>
      <email>Chiara.paoli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Maria Vannucchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grazia Ciardo</last_name>
      <phone>(39 010) 555-3302</phone>
      <email>Ciardomg.82@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Massimo Lemoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo, Università degli studi di Pavi</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Carolei</last_name>
      <phone>(39 0382) 502-767</phone>
      <email>a.carolei@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Rosti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Artuso</last_name>
      <phone>(39 02) 5503-5420</phone>
      <email>silvia.artuso@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Iurlo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Deambrogi</last_name>
      <phone>(39 032) 166-0655</phone>
      <email>clara.deambrogi@med.uniupo.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Patriarca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Prota</last_name>
      <phone>(39 0541) 705-866</phone>
      <email>Dora.prota@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Simona Tomassetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessia Ingrassia</last_name>
      <phone>(39 033) 239-3904</phone>
      <email>alessia.ingrassia@asst-settelaghi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Passamonti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Vrije Universiteit</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 BT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tineke Kruijt</last_name>
      <phone>(31 20) 444-4790</phone>
      <email>j.kruijt@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Marielle Wondergem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universiteit Maastricht Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Geesing</last_name>
      <phone>(31 43) 388-2901</phone>
      <email>research.hematologie@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Gwendolyn Van Gorkom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Universitair Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selina van Zelst</last_name>
      <phone>(31 10) 704-0704</phone>
      <email>s.vanzelst@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Peter Te Boekhorst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Religa</last_name>
      <phone>(48 58) 349-2230</phone>
      <email>areliga@uck.gda.pl</email>
    </contact>
    <investigator>
      <last_name>Witold Prejzner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPZOZ Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylwia Czekalska</last_name>
      <phone>(48 60) 674-9792</phone>
      <email>sczekalska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tomasz Sacha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Jusko</last_name>
      <email>mjusko@ihit.waw.pl</email>
    </contact>
    <investigator>
      <last_name>Ilona Seferynska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Todd</last_name>
      <phone>(44 289) 032-9241</phone>
      <email>joanne.todd@belfasttrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Mary McMullin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Jones</last_name>
      <phone>(44 1223) 331-153</phone>
      <email>thomas.jones@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anna Godfrey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Jones</last_name>
      <phone>(44 29) 2073-6011</phone>
      <email>marc.jones4@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steven Knapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brodie Mckirdle</last_name>
      <phone>(44 141) 301-7000</phone>
      <email>Brodie.mckirdle@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Drummond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Headington</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Lomas</last_name>
      <phone>(44 1865) 235-234</phone>
      <email>rosie.lomas@oncology.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Adam Mead</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Connolly</last_name>
      <phone>(44 151) 334-1155</phone>
      <email>Laura.connolly3@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Nauman Butt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital's NHS foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faustine Laval</last_name>
      <phone>(44 203) 447-7240</phone>
      <email>faustine.laval@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan Lambert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' Hospital - Haematology</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Ale</last_name>
      <phone>(44 20) 7188-2739</phone>
      <email>Esther.ale@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Claire Harrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan James Roberts</last_name>
      <phone>(44 161) 918-2309</phone>
      <email>Ryanjames.roberts@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tim Somervaille</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Oncology</keyword>
  <keyword>BET Inhibitor</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>Pelabresib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

